Global Constipation Treatment Market: Snapshot

The demand in the global market for constipation treatment is projected to increment at a healthy CAGR of 7.1% during the forecast period of 2017 to 2025. This prosperity of the constipation treatment market is primarily a reflection of escalating geriatric population across the globe, as people aged over 50 years are highly prone to irregular bowel movement. Consistent research and development to develop novel drugs that are more efficient, improving healthcare infrastructure in various emerging economies, and growing awareness among the end-users are some of the other factors favoring the global constipation treatment market. On the other hand, continued reliance of the patients on over-the-counter drugs and vast unmet demands in rural areas of developing countries is hindering the proper prosperity of the global constipation treatment market. Evaluated to have a worth of US$12.58 bn in 2016, the global constipation treatment market is estimated to reach a valuation of US$22.93 bn by the end of the forecast period, which is 2025.

 

constipation treatment market

 

Laxatives Remain Highly Profitable Therapeutic Segment

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. In 2016, the laxatives segment, which is further categorized into bulk forming agents, stimulant laxatives, and osmotic laxatives, accounted for the maximum demand-share. Over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment. That being said, GC-C agonists segment is projected for the best CAGR of 8.7% from 2017 to 2025.

Based on the type of disease, the global constipation treatment market is bifurcated into irritable bowel syndrome with constipation, chronic idiopathic constipation, and opioid induced constipation. The opioid induced constipation segment is projected to expand at CAGR of 7.5% during the forecast period from 2017 to 2025. Based on distribution channel, global market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies segment is projected to hold major share of global constipation treatment market in the near future.

Asia Pacific Projected for Most Impressive Growth Rate

Geographically, the global constipation treatment market has been classified into six major regions, viz. North America, Asia Pacific, Europe, Latin America, The Middle East & Africa, and Commonwealth of Independent States. In 2017, North America served the maximum demand in the constipation treatment market, owing to high prevalence of chronic constipation, high per capita healthcare expenditure, and availability of specialty constipation medicines. The North America constipation market is estimated to be worth US$9.98 bn by the end of 2025. Europe currently is second most lucrative region for the vendors operating in this market, however, Asia Pacific is anticipated to turn into a region-of-focus, with its considerably established market in emerging economies. Japan, India, and China are identified as three emerging country-wide markets for constipation treatment.

Some of the key players currently holding a position of strength in the global constipation market are: Bayer AG, Ironwood Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Limited, Sanofi, AstraZeneca, Abbott Laboratories, Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, Inc., Janssen Pharmaceutical Company, Daewoong Pharmaceuticals Co. Ltd., Prestige Brands Holdings, Inc., Shionogi & Co., Ltd., Renexxion, LLC., Albireo Pharma, Inc., and Cosmo Pharmaceuticals NV.

New Medical Management Approaches Enrich Constipation Treatment Market

Constipation has been associated with high prevalence among worldwide populations, with chronic constipation usually leading to a dramatic fall in the quality of life in affected individuals. The high costs of OTC laxatives, due to prolonged reliance, and frequent doctor visits are factors that add to the psychological distress. Thus, there is a massive unmet need for proper medical management of chronic, propelling lifestyle modifications and medications. A severe case of distress comes from constipation-predominant irritable bowel syndrome (IBS). Aside from the common recommendations for lifestyle modifications, pharmacologic management has gained widespread traction in adolescents and young adults. Growing research in medical management of constipation is a key trend bolstering the growth potential of the constipation treatment market. Advances in diagnostic technologies and the chronic nature of the conditions force individuals to undergo extensive diagnostic evaluation. The growing number of patients diagnosed with rectal sensorimotor dysfunction has spurred R&D in the constipation treatment market. Some of the common diagnostic evaluations propelling the demand for medical management of constipation are endoscopy, anorectal manometry, and colonic transit study. Equipment used in these procedures have notably undergone marked technological advancements, aiding in the prognosis of chronic constipation. A number of dietary and drug approaches have emerged for managing chronic constipation, thereby boosting the prospects of the constipation market.

The COVID-19 pandemic and the still emerging outbreaks in new waves have been cause for governments and industry stakeholders. On one hand, policy makers are burdened with responsibility to upgrade the medical infrastructure to meet the drastically changing needs of the pandemic. On the other hand, maintaining a healthy flow of finances and money seems to be an unsurmountable challenge. The work-at-home has become a norm rather than exception and has remained so for the past several months in 2020 and in 2021 also. This has changed the whole dynamics of health and wellness. These disruptions are also likely to play a crucial role redefining the contours of the constipation treatment market in the near future.

Global Constipation Treatment Market: Scope and Methodology

This report on the global constipation treatment market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global constipation treatment market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global constipation treatment market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different types of therapeutic options and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Constipation treatment Market: Segmentation

Constipation is common disease which is estimated to affect each individual once in life time. According to international as well regional guidelines it is characterized by frequency and nature of bowel movement. Less than 2 bowel movements per week, associated with hard stool and strain in passing is termed as constipation. Constipation may be occasional which lasts for few weeks or may be chronic which lasts for longer period and is recurrent. It may be associated with other conditions such as irritable bowel syndrome or opioid consumption.

Based on therapeutic option, the global constipation treatment market has been segmented into laxatives, chloride channel activators, peripherally acting mu opioid receptor antagonists, GC-C agonists and 5-HT4 receptor agonists. The laxatives segment is further classified into bulk forming agents, osmotic laxatives, stimulant laxatives, and others. The laxatives segment is anticipated to hold a dominating share of the global market. The GC-C agonists segment is projected to have exponential growth during the forecast period due to efficacy and launch of new products.

Based on disease type, the global constipation treatment market is segmented into chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) and opioid induced constipation (OIC). High prevalence of chronic constipation is estimated to contribute for dominating share of CIC segment in global market while increasing opioid consumption is projected to propel for exponential growth of OIC segment during forecast period.

Based on the distribution channel, the global constipation treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Ever increasing number of retail pharmacies, self-medication with widely available OTC laxatives is attributed for the significant share of the segment in the global market.

Constipation treatment Market: Geographical and Competitive Dynamics

Geographically, the global constipation treatment market has been segmented into six regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa and Commonwealth of Independent States. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the constipation treatment market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Ironwood Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Limited, Valeant Pharmaceuticals International, Inc., Abbott Laboratories, AstraZeneca, Valeant Pharmaceuticals International, Inc., Cosmo Pharmaceuticals NV, Sanofi, Daewoong Pharmaceuticals Co. Ltd., Bayer AG, Prestige Brands Holdings, Inc., Janssen Pharmaceutical Company, Shionogi & Co., Ltd., Albireo Pharma, Inc., and Renexxion, LLC.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global constipation treatment market has been segmented as below:

by Therapeutic Option

  • Laxatives
    • Bulk forming agents
    • Osmotic laxatives
    • Stimulant laxatives
    • Others
  • Chloride channel activators
  • Peripherally Acting Mu-Opioid Receptor Antagonists
  • GC-C Agonists
  • 5-HT4 Receptor Agonists

by Disease Type

  • Chronic idiopathic constipation (CIC)
  • Irritable bowel syndrome with constipation (IBS-C)
  • Opioid-induced constipation (OIC)

by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

by Switches and Multiplexer Type

  • Analog
  • Buffered
  • Protocol Specific

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Philippines
    • Thailand
    • Indonesia
    • Malaysia
    • Singapore
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Ecuador
    • Peru
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa
  • Commonwealth of Independent States
    • Russian Federation
    • Ukraine
    • Kazakhstan

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Constipation Treatment Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Market Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunities
     4.5. Constipation Treatment Market Analysis and Forecast, 2017 – 2025
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s five forces analysis
     4.7. Global Prevalence of Chronic Constipation
     4.8. Global Prevalence if Irritable Bowel Syndrome
     4.9. Pipeline Analysis
     4.10. Value Chain Analysis
     4.11. Market Outlook

5. Global Constipation Treatment Market Analysis and Forecasts, By Therapeutic Option
     5.1. Introduction & Definition
     5.2. Key Findings
     5.3. Key Trends
     5.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
            5.4.1. Laxatives
                       5.4.1.1. Bulk forming agents
                       5.4.1.2. Osmotic laxatives
                       5.4.1.3. Stimulant laxatives
                       5.4.1.4. Others
            5.4.2. Chloride channel activators
            5.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            5.4.4. GC-C Agonists
            5.4.5. 5-HT4 Receptor Agonists
     5.5. New Chronic Constipation Therapies Market Revenue (US$) Forecast, 2017-2025
     5.6. Market Attractiveness, By Therapeutic Option

6. Global Constipation Treatment Market Analysis and Forecasts, By Disease Type
     6.1. Introduction & Definition
     6.2. Key Findings 
     6.3. Key Trends
     6.4. Market Size (US$ Mn) Forecast, By Disease Type
            6.4.1. Chronic idiopathic constipation (CIC)
            6.4.2. Irritable bowel syndrome with constipation (IBS-C)
            6.4.3. Opioid-induced constipation (OIC)
     6.5. Market Attractiveness, By Disease Type

7. Global Constipation Treatment Market Analysis and Forecasts, By Distribution Channel
     7.1. Introduction & Definition
     7.2. Key Findings 
     7.3. Key Trends
     7.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
            7.4.1. Hospital Pharmacies
            7.4.2. Retail Pharmacies
            7.4.3. Online Pharmacies
     7.5. Market Attractiveness, By Distribution Channel

8. Global Constipation Treatment Market Analysis and Forecasts, By Region
     8.1. Introduction & Definition
     8.2. Key Findings 
     8.3. Key Trends
     8.4. Market Size (US$ Mn) Forecast, By Region
            8.4.1. North America
            8.4.2. Europe
            8.4.3. Asia Pacific
            8.4.4. Latin America
            8.4.5. Middle East and Africa
            8.4.6. Commonwealth of Independent States
     8.5. Market Attractiveness, By Region

9. North America Constipation Treatment Market Analysis and Forecast
     9.1. Introduction
     9.2. Key Findings 
     9.3. Key Trends
     9.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
            9.4.1. Laxatives
                       9.4.1.1. Bulk forming agents
                       9.4.1.2. Osmotic laxatives
                       9.4.1.3. Stimulant laxatives
                       9.4.1.4. Others
            9.4.2. Chloride channel activators
            9.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            9.4.4. GC-C Agonists
     9.5. Market Size (US$ Mn) Forecast, By Disease Type
            9.5.1. Chronic idiopathic constipation (CIC)
            9.5.2. Irritable bowel syndrome with constipation (IBS-C)
            9.5.3. Opioid-induced constipation (OIC)
     9.6. Market Size (US$ Mn) Forecast, By Distribution Chanel
            9.6.1. Hospital Pharmacies
            9.6.2. Retail Pharmacies
            9.6.3. Online Pharmacies
     9.7. Market Size by Value (US$ Mn) Forecast, By Country
            9.7.1. The U.S.
            9.7.2. Canada
     9.8. Market Attractiveness Analysis 
            9.8.1. By Therapeutic Option
            9.8.2. By Disease Type
            9.8.3. By Distribution Channel
            9.8.4. By Country

10.  Europe Constipation Treatment Market Analysis and Forecast
     10.1. Introduction
     10.2. Key Findings 
     10.3. Key Trends
     10.4. Market Size (US$ Mn) Forecast, By Therapeutic Option
            10.4.1. Laxatives
                       10.4.1.1. Bulk forming agents
                       10.4.1.2. Osmotic laxatives
                       10.4.1.3. Stimulant laxatives
                       10.4.1.4. Others
            10.4.2. Chloride channel activators
            10.4.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            10.4.4. GC-C Agonists
            10.4.5. 5-HT4 Receptor Agonists
     10.5. Market Size (US$ Mn) Forecast, By Disease Type
            10.5.1. Chronic idiopathic constipation (CIC)
            10.5.2. Irritable bowel syndrome with constipation (IBS-C)
            10.5.3. Opioid-induced constipation (OIC)
     10.6. Market Size (US$ Mn) Forecast, By Distribution Chanel
            10.6.1. Hospital Pharmacies
            10.6.2. Retail Pharmacies
            10.6.3. Online Pharmacies
     10.7. Market Size by Value (US$ Mn) Forecast, By Country
            10.7.1. Germany
            10.7.2. France
            10.7.3. U.K.
            10.7.4. Spain
            10.7.5. Italy
            10.7.6. Rest of Europe
     10.8. Market Attractiveness Analysis 
            10.8.1. By Therapeutic Option
            10.8.2. By Disease Type
            10.8.3. By Distribution Channel
            10.8.4. By Country

11.  Asia Pacific Constipation Treatment Market Analysis and Forecast
     11.1. Introduction
     11.2. Key Findings 
     11.3. Regulatory Scenario 
     11.4. Key Trends
     11.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
            11.5.1. Laxatives
                       11.5.1.1. Bulk forming agents
                       11.5.1.2. Osmotic laxatives
                       11.5.1.3. Stimulant laxatives
                       11.5.1.4. Others
            11.5.2. Chloride channel activators
            11.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            11.5.4. GC-C Agonists
            11.5.5. 5-HT4 Receptor Agonists
     11.6. Market Size (US$ Mn) Forecast, By Disease Type
            11.6.1. Chronic idiopathic constipation (CIC)
            11.6.2. Irritable bowel syndrome with constipation (IBS-C)
            11.6.3. Opioid-induced constipation (OIC)
     11.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
            11.7.1. Hospital Pharmacies
            11.7.2. Retail Pharmacies
            11.7.3. Online Pharmacies
     11.8. Market Size by Value (US$ Mn) Forecast, By Country
            11.8.1. Philippines
            11.8.2. Thailand
            11.8.3. Indonesia
            11.8.4. South Korea
            11.8.5. Singapore
            11.8.6. Malaysia
            11.8.7. Rest of Asia Pacific
     11.9. Market Attractiveness Analysis 
            11.9.1. By Therapeutic Option
            11.9.2. By Disease Type
            11.9.3. By Distribution Channel
            11.9.4. By Country

12.  Latin America Constipation Treatment Market Analysis and Forecast
     12.1. Introduction
     12.2. Key Findings 
     12.3. Regulatory Scenario 
     12.4. Key Trends
     12.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
            12.5.1. Laxatives
                       12.5.1.1. Bulk forming agents
                       12.5.1.2. Osmotic laxatives
                       12.5.1.3. Stimulant laxatives
                       12.5.1.4. Others
            12.5.2. Chloride channel activators
            12.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            12.5.4. GC-C Agonists
            12.5.5. 5-HT4 Receptor Agonists
     12.6. Market Size (US$ Mn) Forecast, By Disease Type
            12.6.1. Chronic idiopathic constipation (CIC)
            12.6.2. Irritable bowel syndrome with constipation (IBS-C)
            12.6.3. Opioid-induced constipation (OIC)
     12.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
            12.7.1. Hospital Pharmacies
            12.7.2. Retail Pharmacies
            12.7.3. Online Pharmacies
     12.8. Market Size by Value (US$ Mn) Forecast, By Country
            12.8.1. Brazil
            12.8.2. Mexico
            12.8.3. Argentina
            12.8.4. Ecuador
            12.8.5. Peru
            12.8.6. Rest of Latin America
     12.9. Market Attractiveness Analysis 
            12.9.1. By Therapeutic Option
            12.9.2. By Disease Type
            12.9.3. By Distribution Channel
            12.9.4. By Country

13.  Middle East and Africa Constipation Treatment Market Analysis and Forecast
     13.1. Introduction
     13.2. Key Findings 
     13.3. Regulatory Scenario      
     13.4. Key Trends
     13.5. Market Size (US$ Mn) Forecast, By Therapeutic Option
            13.5.1. Laxatives
                       13.5.1.1. Bulk forming agents
                       13.5.1.2. Osmotic laxatives
                       13.5.1.3. Stimulant laxatives
                       13.5.1.4. Others
            13.5.2. Chloride channel activators
            13.5.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            13.5.4. GC-C Agonists
            13.5.5. 5-HT4 Receptor Agonists
     13.6. Market Size (US$ Mn) Forecast, By Disease Type
            13.6.1. Chronic idiopathic constipation (CIC)
            13.6.2. Irritable bowel syndrome with constipation (IBS-C)
            13.6.3. Opioid-induced constipation (OIC)
     13.7. Market Size (US$ Mn) Forecast, By Distribution Chanel
            13.7.1. Hospital Pharmacies
            13.7.2. Retail Pharmacies
            13.7.3. Online Pharmacies
     13.8. Market Size by Value (US$ Mn) Forecast, By Country
            13.8.1. Saudi Arabia
            13.8.2. South Africa
            13.8.3. Rest of Middle East and Africa
     13.9. Market Attractiveness Analysis 
            13.9.1. By Therapeutic Option
            13.9.2. By Disease Type
            13.9.3. By Distribution Channel
            13.9.4. By Country

14.  Commonwealth of Independent States Constipation Treatment Market Analysis and Forecast
     14.1. Introduction
     14.2. Key Findings 
     14.3. Market Size (US$ Mn) Forecast, By Therapeutic Option
            14.3.1. Laxatives
                       14.3.1.1. Bulk forming agents
                       14.3.1.2. Osmotic laxatives
                       14.3.1.3. Stimulant laxatives
                       14.3.1.4. Others
            14.3.2. Chloride channel activators
            14.3.3. Peripherally Acting Mu-Opioid Receptor Antagonists
            14.3.4. GC-C Agonists
            14.3.5. 5-HT4 Receptor Agonists
     14.4. Market Size (US$ Mn) Forecast, By Disease Type
            14.4.1. Chronic idiopathic constipation (CIC)
            14.4.2. Irritable bowel syndrome with constipation (IBS-C)
            14.4.3. Opioid-induced constipation (OIC)
     14.5. Market Size (US$ Mn) Forecast, By Distribution Chanel
            14.5.1. Hospital Pharmacies
            14.5.2. Retail Pharmacies
            14.5.3. Online Pharmacies
     14.6. Market Size by Value (US$ Mn) Forecast, By Country
            14.6.1. Russian Federation
            14.6.2. Ukraine
            14.6.3. Kazakhstan
     14.7. Market Attractiveness Analysis 
            14.7.1. By Therapeutic Option
            14.7.2. By Disease Type
            14.7.3. By Distribution Channel
            14.7.4. By Country

15.  Competition Landscape
     15.1. Market Player – Competition Matrix (By Tier and Size of companies)
     15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            15.2.1. Takeda Pharmaceutical Company Ltd
                       15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.1.2. Product Portfolio
                       15.2.1.3. SWOT Analysis
                       15.2.1.4. Financial Overview
                       15.2.1.5. Strategic Overview
            15.2.2. Synergy Pharmaceuticals, Inc.
                       15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.2.2. Product Portfolio
                       15.2.2.3. SWOT Analysis
                       15.2.2.4. Financial Overview
                       15.2.2.5. Strategic Overview
            15.2.3. Sucampo Pharmaceuticals, Inc.
                       15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.3.2. Product Portfolio
                       15.2.3.3. SWOT Analysis
                       15.2.3.4. Financial Overview
                       15.2.3.5. Strategic Overview
            15.2.4. Ironwood Pharmaceuticals, Inc.
                       15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.4.2. Product Portfolio
                       15.2.4.3. SWOT Analysis
                       15.2.4.4. Financial Overview
                       15.2.4.5. Strategic Overview
            15.2.5. Valeant Pharmaceuticals International, Inc.
                       15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.5.2. Product Portfolio
                       15.2.5.3. SWOT Analysis
                       15.2.5.4. Financial Overview
                       15.2.5.5. Strategic Overview
            15.2.6. Abbott Laboratories
                       15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.6.2. Product Portfolio
                       15.2.6.3. SWOT Analysis
                       15.2.6.4. Financial Overview
                       15.2.6.5. Strategic Overview
            15.2.7. AstraZeneca
                       15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.7.2. Product Portfolio
                       15.2.7.3. SWOT Analysis
                       15.2.7.4. Financial Overview
                       15.2.7.5. Strategic Overview
            15.2.8. Cosmo Pharmaceuticals NV
                       15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.8.2. Product Portfolio
                       15.2.8.3. SWOT Analysis
                       15.2.8.4. Financial Overview
                       15.2.8.5. Strategic Overview
            15.2.9. Sanofi
                       15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.9.2. Product Portfolio
                       15.2.9.3. SWOT Analysis
                       15.2.9.4. Financial Overview
                       15.2.9.5. Strategic Overview
            15.2.10. Daewoong Pharmaceuticals Co. Ltd.
                       15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.10.2. Product Portfolio
                       15.2.10.3. SWOT Analysis
                       15.2.10.4. Financial Overview
                       15.2.10.5. Strategic Overview
            15.2.11. Bayer AG
                       15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.11.2. Product Portfolio
                       15.2.11.3. SWOT Analysis
                       15.2.11.4. Financial Overview
                       15.2.11.5. Strategic Overview
            15.2.12. Prestige Brands Holdings, Inc.
                       15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.12.2. Product Portfolio
                       15.2.12.3. SWOT Analysis
                       15.2.12.4. Financial Overview
                       15.2.12.5. Strategic Overview
            15.2.13. Janssen Pharmaceutical Company
                       15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.13.2. Product Portfolio
                       15.2.13.3. SWOT Analysis
                       15.2.13.4. Financial Overview
                       15.2.13.5. Strategic Overview
            15.2.14. Shionogi & Co., Ltd.
                       15.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.14.2. Product Portfolio
                       15.2.14.3. SWOT Analysis
                       15.2.14.4. Financial Overview
                       15.2.14.5. Strategic Overview
            15.2.15. Albireo Pharma, Inc.
                       15.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.15.2. Product Portfolio
                       15.2.15.3. SWOT Analysis
                       15.2.15.4. Financial Overview
                       15.2.15.5. Strategic Overview
            15.2.16. Renexxion, LLC
                       15.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
                       15.2.16.2. Product Portfolio
                       15.2.16.3. SWOT Analysis
                       15.2.16.4. Strategic Overview

16. Key Takeaways

List of Tables

Table 01: Pipeline Analysis, By Phase 3 Drugs
Table 02 : Pipeline Analysis, By Phase 2 (1/2)
Table 03: Pipeline Analysis, By phase 2 (2/2)
Table 04: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
Table 05: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Laxatives, 2015–2025
Table 06: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 07: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 08: Global Constipation Treatment Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 09: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option,2015–2025
Table 10: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
Table 11: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 12: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel,2015–2025
Table 13: North America Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region,2015–2025
Table 14: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
Table 15: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
Table 16: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 17: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 18: Europe Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 19: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
Table 20: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
Table 21: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 22: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 23: Asia Pacific Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 24: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option,2015–2025
Table 25: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
Table 26: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 27: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel,2015–2025
Table 28: Latin America Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 29: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
Table 30: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
Table 31: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 32: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 33: Middle East & Africa Constipation Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 34: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Therapeutic Option, 2015–2025
Table 35: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2015–2025
Table 36: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 37: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 38: CIS Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025

List of Figures

Figure 01: Global Constipation Treatment Market, by Therapeutic Option, Market Size (US$ Mn), 2016 (A)
Figure 02: Global Constipation Treatment Market Revenue (%), by Disease Type, 2016 (A)
Figure 03: Global Constipation Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 04: Global Prevalence of Constipation
Figure 05: Global Prevalence of Irritable Bowel Syndrome
Figure 06: Market Value Share, by Therapeutic Option (2016)
Figure 07: Market Value Share, by Disease Type (2016)
Figure 08: Market Value Share, by Distribution Channel (2016)
Figure 09: Global Constipation Treatment Market Value Share, by Therapeutic Option, 2016 and 2025
Figure 10: Global Constipation Treatment Market Attractiveness, by Therapeutic Option, 2017–2025
Figure 11: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Laxatives, 2015–2025
Figure 12: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chloride Channel Activator, 2015–2025
Figure 13: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by PAMORA 2015–2025
Figure 14: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by GC-C Agonists, 2015–2025
Figure 15: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by 5-HT4 Receptor Agonists 2015–2025
Figure 16: Global Constipation Treatment Market Value Share, by Disease Type, 2016 and 2025
Figure 17: Global Constipation Treatment Market Attractiveness, by Disease Type, 2017–2025
Figure 18: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CIC, 2015–2025
Figure 19: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by IBS-C, 2015–2025
Figure 20: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by OIC, 2015–2025
Figure 21: Global Constipation Treatment Market Value Share, by Distribution Channel, 2016 and 2025
Figure 22: Global Constipation Treatment Market Attractiveness, by Distribution Channel, 2017–2025
Figure 23: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 24: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
Figure 25: Global Constipation Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
Figure 26: Global Constipation Treatment Market Value Share, by Region, 2017 and 2025 
Figure 27: Global Constipation Treatment Market Attractiveness, by Region, 2017–2025
Figure 28: North America Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 29: North America Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
Figure 30: North America Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 31: North America Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 32: North America Constipation Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 33: North America Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
Figure 34: North America Constipation Treatment Market Attractiveness Analysis, by Disease Type
Figure 35: North America Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
Figure 36: North America Constipation Treatment Market Attractiveness Analysis, by Country
Figure 37: Europe Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 38: Europe Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
Figure 39: Europe Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 40: Europe Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 41: Europe Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 42: Europe Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
Figure 43: Europe Constipation Treatment Market Attractiveness Analysis, by Disease Type
Figure 44: Europe Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
Figure 45: Europe Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region
Figure 46: Asia Pacific Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 47: Asia Pacific Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
Figure 48: Asia Pacific Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 49: Asia Pacific Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 50: Asia Pacific Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 51: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
Figure 52: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Disease Type
Figure 53: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
Figure 54: Asia Pacific Constipation Treatment Market Attractiveness Analysis, by Country
Figure 55: Latin America Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 56: Latin America Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
Figure 57: Latin America Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 58: Latin America Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 59: Latin America Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 60: Latin America Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
Figure 61: Latin America Constipation Treatment Market Attractiveness Analysis, by Disease Type
Figure 62: Latin America Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
Figure 63: Latin America Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region
Figure 64: Middle East & Africa Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 65: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
Figure 66: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 67: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 68: Middle East & Africa Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 69: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
Figure 70: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Disease Type
Figure 71: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
Figure 72: Middle East & Africa Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region
Figure 73: CIS Constipation Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 74: CIS Constipation Treatment Market Value Share Analysis, by Therapeutic Option, 2016 and 2025
Figure 75: CIS Constipation Treatment Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 76: CIS Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 77: CIS Constipation Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 78: CIS Constipation Treatment Market Attractiveness Analysis, by Therapeutic Option
Figure 79: CIS Constipation Treatment Market Attractiveness Analysis, by Disease Type
Figure 80: CIS Constipation Treatment Market Attractiveness Analysis, by Distribution Channel 
Figure 81: CIC Constipation Treatment Market Attractiveness Analysis, by Country/Sub-region

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Constipation Treatment Market